Vaccine Design and Testing – Products

Although most mutations have minimal impact on the characteristics of the virus, some may affect its transmissibility, the severity of associated diseases and the efficacy of diagnostics, preventives and treatments.

Octet® BLI platforms are helping accelerate research on Coronavirus by providing:

High-throughput kinetic interaction analysis solutions to rapidly select and characterize vaccine and therapeutic candidates

Efficient workflows for vaccine and biotherapeutic development research

Fast and flexible platform 

Versatile solutions in upstream and downstream vaccine development

AMSBIO has announced new additions to its portfolio of tools for COVID-19 research - two monoclonal antibodies that recognize the Spike RBD (B.1.1.529, Omicron Variant) protein and neutralizes its interaction with ACE2.

Sino Biological, Inc. has announced that it has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus, which quickly raised concerns around the world because of the high number of mutations it carries, especially the 30-plus mutations on the Spike protein.

Charged Aerosol detection (CAD) can be used to complement your HPLC-UV analysis in a situation where excipients in a formula are a mix of UV active and inactive components. Using these tools together gives you a robust and reliable analytical detection method to determine the stability of all vaccine excipients.

BioNet and BIA Separations, now part of Sartorius, have announced the successful development of an optimized mRNA manufacturing process.

At the American Society of Mass Spectrometry conference October 31 to November 4 in Philadelphia, 908 Devices Inc. presented several talks and posters on the use of high-pressure mass spectrometry and microfluidics separation technologies to accelerate drug discovery workflows, including in metabolomics and proteomics applications.

In this cell and gene therapy insights expert roundtable, a panel of four experts will answer some central questions surrounding the development of novel biotherapeutics.

Personalized vaccine strategies minimize deaths and case numbers in a Coronavirus wave of "Variants of Concern" when vaccine supply is limited, a modelling study from Switzerland predicts

Novel and emerging infectious diseases can be a serious threat to human health and the global economy, as exhibited by the current SARS-CoV-2 outbreak. To mitigate these threats, it is necessary to initiate comprehensive containment strategies such as